Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

10 results
Display

Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Kim DY, Nam J, Chung Js, Kim SW, Shin HJ

Purpose There are unmet needs associated with the current treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to the poor treatment outcomes of these strategies. Roflumilast, a selective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Genomics of diffuse large B cell lymphoma

Koh Y

Next generation sequencing (NGS) technology has revealed the heterogeneity of diffuse large B-cell lymphoma (DLBCL) from a mutation perspective. Accordingly, the conventional cell of origin-based classification of DLBCL has changed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Curcumin Inhibits the Proliferation, Migration, Invasion, and Apoptosis of Diffuse Large B-Cell Lymphoma Cell Line by Regulating MiR-21/VHL Axis

Chen L, Zhan CZ, Wang T, You H, Yao R

PURPOSE: Curcumin exerts its anti-cancer effects, partly by targeting special microRNAs, in human cancers. MiR-21 is a key oncomir in carcinogenesis of multiple human cancers. Here, we aimed to further...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma

Kim DY, Song MK, Chung JS, Shin HJ, Yang DH, Lim SN, Oh SY

BACKGROUND: Systemic inflammatory response can be associated with the prognosis of diffuse large B cell lymphoma (DLBCL). We investigated the systemic factors significantly related to clinical outcome in relapsed/refractory DLBCL. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma

Eskandari , Manoochehrabadi S, Pashaiefar H, Zaimy MA, Ahmadvand

BACKGROUND: Cell-free DNA (cfDNA) has the potential to serve as a non-invasive prognostic biomarker in some types of neoplasia. The investigation of plasma concentration of cfDNA may reveal its use...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Significance of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP

Park LC, Lee HS, Lee EM, Shin SH, Kim YS

OBJECTIVES: The both values of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) were reported as indexes of systemic inflammation and readily available and inexpensive prognostic markers in patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Utility Analysis for Pegfilgrastim in DLBCL Patients on R-CHOP Regimen

Jung HW, Kim JM, Min MS, Lee YM, Bang JS

OBJECTIVE: This study was designed to compare pegfilgrastim and filgrastim in diffuse large B-cell lymphoma (DLBCL) patients treated with a rituximab with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP) regimen in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy

Oh S, Koo DH, Suh C, Kim S, Park BH, Kang J, Huh J

Many predictive models have been proposed for better stratification of diffuse large B-cell lymphoma (DLBCL). Hans' algorithm has been widely used as standard to sub-classify DLBCL into germinal center B-cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B cell lymphoma treated with R-CHOP

Kim SN, Chae YS, Kim JG, Moon JH, Lee SJ, Kim YJ, Lee YJ, Sohn SK

  • KMID: 2257387
  • Korean J Med.
  • 2009 Jan;76(1):52-59.
BACKGROUND/AIMS: The International Prognostic Index (IPI) and absolute lymphocyte count (ALC) are prognostic factors in diffuse large B cell lymphoma (DLBCL). Nevertheless, in the Rituximab era, a new predictive marker...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rituximab and ESHAP as Second-line Therapy for Relapsed or Primary Refractory Diffuse Large B Cell Lymphoma: The Experience of a Single Center in Korea

Ko OB, Kim S, Lee DH, Kim SW, Huh J, Suh C

BACKGROUND: The remission status prior to autologous stem cell transplantation (ASCT) influences the transplantation outcome in patients with relapsed or primary refractory diffuse large B cell lymphoma (DLBCL), a complete...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr